Asian age-related macular degeneration: Current concepts and gaps in knowledge

Asia-Pacific Journal of Ophthalmology

Volumn 2, Issue 1, 2013, Pages 32-41

  Lim, Laurence Shen ^a   Cheung, Chui Ming Gemmy ^a   Wong, Tien Yin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Age related macular degeneration; Polypoidal choroidal vasculopathy

Indexed keywords

EID: 84904680969     PISSN: None     EISSN: 21620989     Source Type: Journal    
DOI: 10.1097/APO.0b013e31827ff5bc     Document Type: Review

References (171)

1. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet. 2012;379:1728-1738.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
5. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? Prog Retin Eye Res. 2010;29:19-29.
6. Lim TH, Laude A, Tan CS. Polypoidal choroidal vasculopathy: An angiographic discussion. Eye (Lond). 2010;24:483-490.
7. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001;108:697-704.
8. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology. 2010;117:921-927.
9. Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: The Beaver Dam Eye Study. Ophthalmology. 2007;114:253-262.
10. Choudhury F, Varma R, McKean-Cowdin R, et al. Risk factors for four-year incidence and progression of age-related macular degeneration: The Los Angeles Latino Eye Study. Am J Ophthalmol. 2011; 152: 385-395.
11. Yasuda M, Kiyohara Y, Hata Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009; 116: 2135-2140.
12. Ladas ID, Rouvas AA, Moschos MM, et al. Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population. Eye (Lond). 2004;18:455-459.
13. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000;238:752-759.
14. Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117:1503-1510.
15. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15-22.
16. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115:478-485.
17. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2007;245:1441-1445.
18. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392-1396.
19. Byeon SH, Lee SC, Oh HS, et al. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol. 2008;52:57-62.
20. Chen SJ, Cheng CY, Peng KL, et al. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: The Shihpai Eye Study. Invest Ophthalmol Vis Sci. 2008;49:3126-3133.
21. Song SJ, Youm DJ, Chang Y, et al. Age-related macular degeneration in a screened South Korean population: Prevalence, risk factors, and subtypes. Ophthalmic Epidemiol. 2009;16:304-310.
22. Mori K, Horie-Inoue K, Gehlbach PL, et al. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology. 2010;117:928-938.
23. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367-374.
24. Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450-1460.
25. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
26. Klein R, Clegg L, Cooper LS, et al. Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol. 1999;117:1203-1210.
27. Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486-495.
28. Friedman DS, Katz J, Bressler NM, et al. Racial differences in the prevalence of age-related macular degeneration: The Baltimore Eye Survey. Ophthalmology. 1999;106:1049-1055.
29. Wong TY, Loon SC, Saw SM. The epidemiology of age related eye diseases in Asia. Br J Ophthalmol. 2006;90:506-511.
30. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
31. Chakravarthy U. Age related macular degeneration. BMJ. 2006;333:869-870.
32. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
33. Cruickshanks KJ, Hamman RF, Klein R, et al. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy. Arch Ophthalmol. 1997;115:242-250.
34. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
35. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621-1624.
36. Mitchell P, Wang JJ, Foran S, et al. Five-year incidence of age-related maculopathy lesions: The Blue Mountains Eye Study. Ophthalmology. 2002;109:1092-1097.
37. Tomany SC, Klein R, Klein BE. The relationship between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 2003; 110: 1526-1533.
38. Buch H, Nielsen NV, Vinding T, et al. 14-year incidence, progression, and visual morbidity of age-related maculopathy: The Copenhagen City Eye Study. Ophthalmology. 2005;112:787-798.
39. Cugati S, Mitchell P, Rochtchina E, et al. Cataract surgery and the 10-year incidence of age-related maculopathy: The Blue Mountains Eye Study. Ophthalmology. 2006;113:2020-2025.
40. Wang JJ, Klein R, Smith W, et al. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: Pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology. 2003;110:1960-1967.
41. Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of age-related cataract and cataract surgery in an older australian population The Blue Mountains Eye Study. Ophthalmology. 2008; 115:808-814.
42. Freeman EE, Munoz B, West SK, et al. Is there an association between cataract surgery and age-related macular degeneration? Data from three population-based studies. Am J Ophthalmol. 2003;135:849-856.
43. Chaine G, Hullo A, Sahel J, et al. Case-control study of the risk factors for age related macular degeneration. France-DMLA Study Group. Br J Ophthalmol. 1998;82:996-002.
44. Sandberg MA, Tolentino MJ, Miller S, et al. Hyperopia and neovascularization in age-related macular degeneration. Ophthalmology. 1993;100:1009-1013.
45. Maltzman BA, Mulvihill MN, Greenbaum A. Senile macular degeneration and risk factors: A case-control study. Ann Ophthalmol. 1979;11:1197-1201.
46. Lavanya R, Kawasaki R, Tay WT, et al. Hyperopic refractive error and shorter axial length are associated with age-related macular degeneration: The Singapore Malay Eye Study. Invest Ophthalmol Vis Sci. 2010;51:6247-6252.
47. Xu L, You QS, Jonas JB. Refractive error, ocular and general parameters and ophthalmic diseases. The Beijing Eye Study. Graefes Arch Clin Exp Ophthalmol. 2010;248:721-729.
48. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.
49. Clemons TE, Milton RC, Klein R, et al. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533-539.
50. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: The US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol. 2006;124:995-1001.
51. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence of age-related maculopathy and smoking and drinking: The Beaver Dam Eye Study. Am J Epidemiol. 2002;156:589-598.
52. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.
53. Seddon JM, Cote J, Davis N, et al. Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003;121:785-792.
54. Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. Arch Ophthalmol. 1993;111:514-518.
55. Tomany SC, Cruickshanks KJ, Klein R, et al. Sunlight and the 10-year incidence of age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol. 2004;122:750-757.
56. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol. 1992;110: 1701-1708.
57. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology. 2002;109:1767-1779.
58. Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and age-related maculopathy. The Blue Mountains Eye Study. Ophthalmology. 1998;105:1359-1363.
59. Cruickshanks KJ, Klein R, Klein BE, et al. Sunlight and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:246-250.
60. Delcourt C, Diaz JL, Ponton-Sanchez A, et al. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol. 1998;116:1031-1035.
61. Hyman LG, Lilienfeld AM, Ferris FL III, et al. Senile macular degeneration: A case-control study. Am J Epidemiol. 1983;118:213-227.
62. McCarty CA, Mukesh BN, Fu CL, et al. Risk factors for age-related maculopathy: The Visual Impairment Project. Arch Ophthalmol. 2001;119:1455-1462.
63. Klein R, Klein BE, Linton KL, et al. The Beaver Dam Eye Study: The relation of age-related maculopathy to smoking. Am J Epidemiol. 1993;137:190-200.
64. Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114:1518-1523.
65. Seddon JM, Willett WC, Speizer FE, et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141-1146.
66. Vingerling JR, Hofman A, Grobbee DE, et al. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol. 1996;114:1193-1196.
67. Cackett P, Wong TY, Aung T, et al. Smoking, cardiovascular risk factors, and age-related macular degeneration in Asians: The Singapore Malay Eye Study. Am J Ophthalmol. 2008;146:960-967.
68. Kikuchi M, Nakamura M, Ishikawa K, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology. 2007;114:1722-1727.
69. Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology. 2007;114:732-737.
70. Wong TY, Tikellis G, Sun C, et al. Age-related macular degeneration and risk of coronary heart disease: The Atherosclerosis Risk in Communities Study. Ophthalmology. 2007;114:86-91.
71. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med. 2006;145:98-106.
72. Cugati S, Cumming RG, SmithW, et al. Visual impairment, age-related macular degeneration, cataract, and long-term mortality: The Blue Mountains Eye Study. Arch Ophthalmol. 2007;125:917-924.
73. Wong TY. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148:327-329.
74. Liao D, Mo J, Duan Y, et al. Is age-related macular degeneration associated with stroke among elderly americans? Open Ophthalmol J. 2008;2:37-42.
75. Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol. 2008;92:509-512.
76. Hu CC, Ho JD, Lin HC. Neovascular age-related macular degeneration and the risk of stroke: A 5-year population-based follow-up study. Stroke. 2010;41:613-617.
77. Grassi MA, Fingert JH, Scheetz TE, et al. Ethnic variation in AMD-associated complement factor H polymorphism p.Tyr402His. Hum Mutat. 2006;27:921-925.
78. Lau LI, Chen SJ, Cheng CY, et al. Association of the Y402H polymorphism in complement factor H gene and neovascular agerelated macular degeneration in Chinese patients. Invest Ophthalmol Vis Sci. 2006;47:3242-3246.
79. Jiang H, Qu Y, Dang G, et al. Analyses of single nucleotide polymorphisms and haplotype linkage of LOC387715 and the HTRA1 gene in exudative age-related macular degeneration in a Chinese cohort. Retina. 2009;29:974-979.
80. Kaur I, Katta S, Hussain A, et al. Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. Invest Ophthalmol Vis Sci. 2008;49:1771-1776.
81. Lin JM, Wan L, Tsai YY, et al. HTRA1 polymorphism in dry and wet age-related macular degeneration. Retina. 2008;28:309-313.
82. Mori K, Horie-Inoue K, Kohda M, et al. Association of the HTRA1 gene variant with age-related macular degeneration in the Japanese population. J Hum Genet. 2007;52:636-641.
83. Mori K, Gehlbach PL, Kabasawa S, et al. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. Invest Ophthalmol Vis Sci. 2007;48:5315-5319.
84. Xu Y, Guan N, Xu J, et al. Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population. Mol Vis. 2008;14: 1373-1381.
85. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989-992.
86. Francis PJ, Zhang H, Dewan A, et al. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. Mol Vis. 2008;14:1395-1400.
87. Yang Z, Camp NJ, Sun H, et al. Avariant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006; 314:992-993.
88. Yoshida T, Dewan A, Zhang H, et al. HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration. Mol Vis. 2007;13:545-548.
89. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-3236.
90. Kondo N, Honda S, Ishibashi K, et al. LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. Am J Ophthalmol. 2007; 144:608-612.
91. Schaumberg DA, Hankinson SE, Guo Q, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol. 2007;125:55-62.
92. Seitsonen SP, Onkamo P, Peng G, et al. Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration. PLoS ONE. 2008;3:e3833.
93. Cameron DJ, Yang Z, Gibbs D, et al. HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration. Cell Cycle. 2007;6:1122-1125.
94. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol. 1998;116:1646-1651.
95. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227-7232.
96. Wang JJ, Ross RJ, Tuo J, et al. The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study. Ophthalmology. 2008; 115: 693-699.
97. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77:389-407.
98. Schmidt S, Hauser MA, Scott WK, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006;78:852-864.
99. Neuner B, Wellmann J, Dasch B, et al. LOC387715, smoking and their prognostic impact on visual functional status in age-related macular degenerationVThe Muenster Aging and Retina Study (MARS) cohort. Ophthalmic Epidemiol. 2008;15:148-154.
100. Seddon JM, George S, Rosner B, et al. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered. 2006;61: 157-165.
101. Yu Y, Bhangale TR, Fagerness J, et al. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet. 2011;20:3699-3709.
102. Zuo C, Wen F, Li M, et al. COL1A2 polymorphic markers confer an increased risk of neovascular age-related macular degeneration in a Han Chinese population. Mol Vis. 2012;18:1787-1793.
103. Lee KY, Vithana EN, Mathur R, et al. Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:2613-2619.
104. Seddon JM, Reynolds R, Rosner B. Associations of smoking, body mass index, dietary lutein, and the LIPC gene variant rs10468017 with advanced age-related macular degeneration. Mol Vis. 2010; 16: 2412-2424.
105. Nakanishi H, Yamashiro K, Yamada R, et al. Joint effect of cigarette smoking and CFH and LOC387715/HTRA1 polymorphisms on polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2010;51:6183-6187.
106. Chen H, Liu K, Chen LJ, et al. Genetic associations in polypoidal choroidal vasculopathy: A systematic review and meta-analysis. Mol Vis. 2012;18:816-829.
107. Kondo N, Honda S, Ishibashi K, et al. Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:1101-1105.
108. Sun E, Lim A, Liu X, et al. Apolipoprotein E gene and age-related macular degeneration in a Chinese population. Mol Vis. 2011;17: 997-1002.
109. Gotoh N, Kuroiwa S, Kikuchi T, et al. Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Am J Ophthalmol. 2004;138:567-573.
110. Park DH, Kim IT. Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population. Jpn J Ophthalmol. 2012;56:145-151.
111. Nakashizuka H, Mitsumata M, Okisaka S, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:4729-4737.
112. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456-462.
113. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128-1134.
114. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.
115. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: The blue Mountains Eye Study. Ophthalmology. 2007;114:92-98.
116. Bessho H, Honda S, Imai H, et al. Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up. Retina. 2011;31:1598-1602.
117. Hou J, Tao Y, Li XX, et al. Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2011;249:975-979.
118. Anantharaman G, Ramkumar G, Gopalakrishnan M, et al. Clinical features, management and visual outcome of polypoidal choroidal vasculopathy in Indian patients. Indian J Ophthalmol. 2010;58:399-405.
119. Koh A, Lee WK, Chen LJ, et al. EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy. Retina. 2012;32:1453-1464.
120. Gomi F, Sawa M, Mitarai K, et al. Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1421-1427.
121. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990. Retina. 2012;32(Suppl 1):1-8.
122. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: Natural history. Am J Ophthalmol. 2002;133:639-648.
123. Zhou H, Zhao X, Johnson EJ, et al. Serum carotenoids and risk of age-related macular degeneration in a chinese population sample. Invest Ophthalmol Vis Sci. 2011;52:4338-4344.
124. Wang G, Brun TA, Geissler CA, et al. Vitamin A and carotenoid status in rural China. Br J Nutr. 1996;76:809-820.
125. Michikawa T, Ishida S, Nishiwaki Y, et al. Serum antioxidants and age-related macular degeneration among older Japanese. Asia Pac J Clin Nutr. 2009;18:1-7.
126. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1986;104:694-701.
127. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100:912-918.
128. Rishi P, Das A, Sarate P, et al. Management of peripheral polypoidal choroidal vasculopathy with intravitreal bevacizumab and indocyanine green angiography-guided laser photocoagulation. Indian J Ophthalmol. 2012;60:60-63.
129. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198-207.
130. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6-18.
131. Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007;3:CD002030.
132. Honda S, Kurimoto Y, Kagotani Y, et al. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol. 2009;53:593-597.
133. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:39-44.
134. Lee WK, Kim KS, KimW, et al. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters. Am J Ophthalmol. 2012;154:355-365.
135. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. 2002. Retina. 2012;32(Suppl 1):529-535.
136. Chhablani JK. Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2010;58:552-553.
137. Yamashita A, Shiraga F, Shiragami C, et al. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:465-471.
138. Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File. Am J Ophthalmol. 2011;151:887-895.
139. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
140. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology. 2012;119:1388-1398.
141. Li X, Hu Y, Sun X, et al. Bevacizumab for neovascular age-related macular degeneration in China. Ophthalmology. 2012;119:2087-2093.
142. Tano Y, Ohji M. EXTEND-I: Safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol. 2010;88:309-316.
143. Hikichi T, Higuchi M, Matsushita T, et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol. 2012;154:117-124.
144. Cho HJ, Kim JW, Lee DW, et al. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye (Lond). 2012;26:426-433.
145. Matsumiya W, Honda S, Bessho H, et al. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol. 2011;2011:742020.
146. Wakabayashi T, Gomi F, Sawa M, et al. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol. 2012;96:394-399.
147. Saito M, Iida T, Kano M. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Retina. 2011;31:1589-1597.
148. Kim KS, Lee WK. Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:370-377.
149. Cheng CK, Peng CH, Chang CK, et al. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina. 2011;31:846-856.
150. Tsujikawa A, Ooto S, Yamashiro K, et al. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2010;54:310-319.
151. Cheung CM, Wong TY. Ranibizumab and bevacizumab for AMD. N Engl J Med. 2011;365:2237.
152. Gomi F, Sawa M, Wakabayashi T, et al. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;150:48-54.
153. Kim M, Kim K, Kim dG, et al. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica. 2011; 226: 205-213.
154. Kim SJ, Yu HG. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy. Retina. 2011;31:1827-1834.
155. Lai TY, Lee GK, Luk FO, et al. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina. 2011;31:1581-1588.
156. Lee YH, Lee EK, Shin KS, et al. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy. Retina. 2011;31:1287-1293.
157. Moon SW, Kim MS, Kim ES, et al. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy. Ophthalmologica. 2011;225:169-175.
158. Ricci F, Calabrese A, Regine F, et al. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. Retina. 2012;32:1280-1288.
159. Sagong M, Lim S, Chang W. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2012;153:873-882.
160. Sato T, Kishi S, Matsumoto H, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947-954.
161. Song MH, Ryu HW, Roh YJ. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Ophthalmologica. 2011;226:119-126.
162. Tomita K, Tsujikawa A, Yamashiro K, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol. 2012;153:68-80.
163. Li Y, Xu L, Jonas JB, et al. Prevalence of age-related maculopathy in the adult population in China: The Beijing eye study. Am J Ophthalmol. 2006;142:788-793.
164. Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: The Funagata study. Ophthalmology. 2008;115:1376-1381, 1381.
165. Oguido AP, Casella AM, Matsuo T, et al. Prevalence of age-related macular degeneration in Japanese immigrants and their descendants living in Londrina (PR)VBrazil. Arq Bras Oftalmol. 2008;71: 375-380.
166. Nirmalan PK, Katz J, Robin AL, et al. Prevalence of vitreoretinal disorders in a rural population of southern India: The Aravind Comprehensive Eye Study. Arch Ophthalmol. 2004;122:581-586.
167. Gupta SK, Murthy GV, Morrison N, et al. Prevalence of early and late age-related macular degeneration in a rural population in northern India: The INDEYE feasibility study. Invest Ophthalmol Vis Sci. 2007; 48: 1007-1011.
168. Nangia V, Jonas JB, Kulkarni M, et al. Prevalence of age-related macular degeneration in rural central India: The Central India Eye and Medical Study. Retina. 2011;31:1179-1185.
169. Kawasaki R, Wang JJ, Aung T, et al. Prevalence of age-related macular degeneration in a Malay population: The Singapore Malay Eye Study. Ophthalmology. 2008;115:1735-1741.
170. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, et al. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: Results of a 1-year preliminary study. Br J Ophthalmol. 2010;94:1045-1051.
171. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2005;89:602-607.